慢性音響性耳鳴に対する二峰性電気音響刺激と聴覚トレーニング (NITESGON-ADT)
二峰性電気音響刺激を用いた耳鳴り脳の非侵襲的再トレーニング(NITESGON-ADT):前向き、二重盲検、無作為化比較試験のプロトコル
This study tests whether pairing non-invasive stimulation of the greater occipital nerve (NITESGON) with an attentionally demanding auditory frequency discrimination training task reduces tinnitus loudness and tinnitus-related distress. One hundred adults with chronic tonal tinnitus will be randomised to one of four groups in a 2×2 factorial design: real versus sham NITESGON and active versus passive listening during auditory stimulation. Participants complete eight sessions across four weeks, with outcomes assessed at baseline, end of treatment, 28 days post-treatment, and 6 months post-treatment.
調査の概要
状態
詳細な説明
This is a single-centre, prospective, double-blind, placebo-controlled, 2×2 factorial randomised controlled trial conducted at Trinity College Dublin. The intervention combines transcutaneous electrical stimulation targeting the greater occipital nerve (NITESGON) with auditory stimulation delivered during a structured training paradigm. The two between-subjects factors are stimulation condition (real NITESGON vs sham NITESGON) and listening condition (active listening: auditory frequency discrimination training vs passive listening: visual distractor task while auditory stimuli are presented). One hundred adults with chronic tonal tinnitus will be randomised 1:1:1:1 to one of four arms. Participants complete eight sessions (two per week for four weeks). Primary outcomes-tinnitus loudness (VAS 0-100), tinnitus-related functional impact (TFI 0-100), and tinnitus handicap (THI 0-100)-and secondary outcomes are assessed at baseline (T0), end of treatment (T1), 28 days after treatment completion (T2), and 6 months after treatment completion (T3). Secondary outcomes include EEG (resting-state and auditory oddball), autonomic/biomarker measures (pupillometry, heart rate, saliva), patient global impression of change, quality of life, and safety/blinding assessments.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Anusha Mohan, PhD
- メール:anusha.mohan@tcd.ie
研究連絡先のバックアップ
- 名前:Sven Vanneste, PhD
- 電話番号:+353 87 470 2835.
- メール:sven.vanneste@tcd.ie
研究場所
-
-
Dublin
-
Dublin、Dublin、アイルランド、D02
- 募集
- Trinity College Institute of Neuroscience (TCIN)
-
コンタクト:
- Fabian Broecker
- 電話番号:+353 087 470 2835.
- メール:broeckef@tcd.ie
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 18-80 years
- Continuous subjective tinnitus for >3 months and ≤5 years
- Predominantly tonal tinnitus (unilateral or bilateral)
- Screening THI score 28-76
- Minimum Masking Level (MML) 20-80 dB HL
- No prior tinnitus neuromodulation treatment
- Able to comply with eight sessions over four weeks and follow-up assessments
Exclusion Criteria:
- Objective tinnitus or predominantly somatic tinnitus
- Pulsatile tinnitus
- Evidence of conductive hearing loss (abnormal otoscopy or tympanometry)
- Pure-tone audiometry exclusions: >40 dB HL at any frequency 250 Hz-1 kHz OR >80 dB HL at any frequency 2-8 kHz in either ear
- Hearing aid use initiated within the past 90 days
- Active implantable medical device (e.g., pacemaker, DBS, cochlear implant)
- LDL <30 dB SL at 500 Hz in either ear
- Diagnosis of temporomandibular joint disorder or occipital neuralgia
- Severe anxiety (STAI >120/160)
- Cognitive impairment (MMSE <25)
- Severe depressive symptoms (BDI ≥30)
- Diagnosis of Menière's disease
- Current pregnancy
- Involvement in medicolegal cases
- History of auditory hallucinations
- Current prescription of central nervous system drugs likely to alter neuromodulatory function (e.g., noradrenergic, dopaminergic, serotonergic, benzodiazepine, cholinergic, or other psychoactive medications)
- Currently enrolled in another interventional study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:階乗代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Real Stimulation + Active Listening (ADT)
Real stimulation delivered during active auditory frequency discrimination training. |
Real NITESGON is delivered transcutaneously via two saline-soaked sponge electrodes (35 cm² each) positioned bilaterally over the C2 dermatomes to target the greater occipital nerve. Stimulation consists of a constant direct current of 1.5 mA (tDCS), ramped up over 30 seconds and ramped down over 5 seconds. It is administered concurrently with the task for approximately 45 minutes per session, across eight sessions (2/week) over 4 weeks. ADT is delivered using a three-interval, three-alternative forced-choice (3I-3AFC) frequency discrimination task. Standard tone frequencies are individually selected using equivalent rectangular bandwidth (ERB) spacing, centred on each participant's dominant tinnitus pitch, with five frequencies positioned at -5, -3, -1, +1, and +3 ERB relative to the tinnitus pitch. Frequencies are restricted to the range of 250-13,000 Hz. Tones are presented binaurally via headphones, with presentation levels individually calibrated using audiometric thresholds and frequency-specific reference equivalent threshold sound pressure levels (RETSPLs), subject to the protocol's sound pressure level limits.
他の名前:
|
|
アクティブコンパレータ:Real Stimulation + Passive Listening
Real stimulation delivered while participants perform a visual distractor task and are instructed to ignore auditory stimuli. |
Real NITESGON is delivered transcutaneously via two saline-soaked sponge electrodes (35 cm² each) positioned bilaterally over the C2 dermatomes to target the greater occipital nerve. Stimulation consists of a constant direct current of 1.5 mA (tDCS), ramped up over 30 seconds and ramped down over 5 seconds. It is administered concurrently with the task for approximately 45 minutes per session, across eight sessions (2/week) over 4 weeks. VisDT uses a three-interval, three-alternative forced-choice (3I-3AFC) paradigm with Gabor patches (sinusoidal gratings windowed by a Gaussian envelope) of fixed spatial frequency (6 cycles/degree) and fixed spatial spread. On each trial, one interval contains an orientation deviant relative to the standard. During VisDT, participants attend to the visual task while concurrent binaural tones are presented passively using a predetermined, non-adaptive schedule. Auditory frequencies are individually selected using equivalent rectangular bandwidth (ERB) spacing, centred on each participant's dominant tinnitus pitch, with five frequencies positioned at -5, -3, -1, +1, and +3 ERB relative to the tinnitus pitch. Frequencies are restricted to 250-13,000 Hz, and presentation levels are individually calibrated using audiometric thresholds and frequency-specific reference equivalent threshold sound pressure levels (RETSPLs), subject to the protocol's sound pressure level limits.
他の名前:
|
|
偽コンパレータ:Sham Stimulation + Active Listening (ADT)
Sham stimulation delivered during active auditory frequency discrimination training. |
ADT is delivered using a three-interval, three-alternative forced-choice (3I-3AFC) frequency discrimination task. Standard tone frequencies are individually selected using equivalent rectangular bandwidth (ERB) spacing, centred on each participant's dominant tinnitus pitch, with five frequencies positioned at -5, -3, -1, +1, and +3 ERB relative to the tinnitus pitch. Frequencies are restricted to the range of 250-13,000 Hz. Tones are presented binaurally via headphones, with presentation levels individually calibrated using audiometric thresholds and frequency-specific reference equivalent threshold sound pressure levels (RETSPLs), subject to the protocol's sound pressure level limits.
他の名前:
Sham NITESGON is delivered using two saline-soaked sponge electrodes (35 cm² each) positioned bilaterally over the C2 dermatomes. The sham condition mimics real stimulation sensations via a 30-second ramp-up followed by a brief ramp-down, with no sustained current thereafter. Sham is administered concurrently with the task for ~45 minutes per session, across eight sessions (2/week) over 4 weeks. |
|
偽コンパレータ:Sham Stimulation + Passive Listening
Sham stimulation delivered while participants perform a visual distractor task and are instructed to ignore auditory stimuli. |
VisDT uses a three-interval, three-alternative forced-choice (3I-3AFC) paradigm with Gabor patches (sinusoidal gratings windowed by a Gaussian envelope) of fixed spatial frequency (6 cycles/degree) and fixed spatial spread. On each trial, one interval contains an orientation deviant relative to the standard. During VisDT, participants attend to the visual task while concurrent binaural tones are presented passively using a predetermined, non-adaptive schedule. Auditory frequencies are individually selected using equivalent rectangular bandwidth (ERB) spacing, centred on each participant's dominant tinnitus pitch, with five frequencies positioned at -5, -3, -1, +1, and +3 ERB relative to the tinnitus pitch. Frequencies are restricted to 250-13,000 Hz, and presentation levels are individually calibrated using audiometric thresholds and frequency-specific reference equivalent threshold sound pressure levels (RETSPLs), subject to the protocol's sound pressure level limits.
他の名前:
Sham NITESGON is delivered using two saline-soaked sponge electrodes (35 cm² each) positioned bilaterally over the C2 dermatomes. The sham condition mimics real stimulation sensations via a 30-second ramp-up followed by a brief ramp-down, with no sustained current thereafter. Sham is administered concurrently with the task for ~45 minutes per session, across eight sessions (2/week) over 4 weeks. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Tinnitus Loudness (Visual Analogue Scale, VAS 0-100)
時間枠:Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
0-100 mm VAS anchored from "not audible" to "extremely loud"; higher scores indicate greater perceived tinnitus loudness. |
Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
|
Tinnitus Functional Index (TFI, 0-100)
時間枠:Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
25-item self-report measure of tinnitus-related functional impact; total score 0-100, higher scores indicate greater impairment. |
Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
|
Tinnitus Handicap Inventory (THI, 0-100)
時間枠:Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
25-item measure of tinnitus-related handicap; total score 0-100, higher scores indicate greater handicap. |
Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient Global Impression of Change (PGIC)
時間枠:End of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
Participant-rated global change since baseline using the Patient Global Impression of Change (PGIC) scale (-3 = very much worse to +3 = very much improved; higher scores indicate greater improvement). |
End of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
|
Quality of Life (World Health Organization Quality of Life-BREF questionnaire)
時間枠:Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
Quality of life assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF), yielding domain scores and an overall score (0-100; higher scores indicate better quality of life). |
Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
|
|
Adverse Events (Stimulation Side-Effects Questionnaire)
時間枠:Up to 4 weeks (Sessions 1-8)
|
Stimulation tolerability assessed each visit using a Stimulation Side-Effects Questionnaire recording presence and severity of side effects (e.g., tingling, itching, headache) rated on a numeric severity scale (0-10; higher scores indicate worse side effects), plus event frequency. |
Up to 4 weeks (Sessions 1-8)
|
|
Resting-State EEG Spectral Power (Eyes Open)
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Resting-state eyes-open electroencephalography (EEG) spectral power averaged within prespecified frequency bands and electrode/network regions, reported in decibels (dB); higher values indicate greater spectral power. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
|
Resting-State EEG Functional Connectivity (Eyes open)
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Resting-state eyes-open EEG functional connectivity within prespecified networks, quantified as phase-locking value (PLV; unitless, 0-1); higher values indicate stronger phase synchronization. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
|
Auditory Oddball Task-Evoked Response Amplitude
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Auditory oddball event-related potential (ERP) amplitude (e.g., P300) averaged over prespecified electrodes/time windows, reported in microvolts (µV); higher absolute amplitude indicates larger task-evoked response. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
|
Auditory Oddball Task-Evoked Response Latency
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Auditory oddball ERP component latency (e.g., P300 peak latency) within prespecified time windows, reported in milliseconds (ms); lower values indicate faster evoked responses. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
|
Pupillometry
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Task-related pupil diameter during pupillometry, summarized as mean (or peak) pupil size change from baseline, reported in millimeters (mm); larger values indicate greater pupil dilation. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
|
Heart Rate
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Electrocardiography (ECG)-derived heart rate, reported in beats per minute (bpm); higher values indicate faster heart rate. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
|
Saliva Biomarkers
時間枠:Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
Salivary alpha-amylase activity measured as an exploratory biomarker of autonomic arousal and physiological responses to neuromodulation, reported in units per millilitre (U/mL), subject to the validated assay's reporting units. |
Baseline visit, end of treatment (4 weeks), 28 days post-treatment, and 6 months post-treatment.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。